Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Gilbert MP, et al. Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. Ann Intern Med. 2019. PMID: 30508430 Clinical Trial. No abstract available.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
[Localization techniques in primary hyperparathyroidism].
Muñoz-Torres M, Jodar Gimeno E, Quesada Charneco M, Escobar-Jiménez F. Muñoz-Torres M, et al. Med Clin (Barc). 1993 Jul 3;101(6):239. Med Clin (Barc). 1993. PMID: 8332028 Spanish. No abstract available.
Results from a national survey on the management of primary hyperparathyroidism.
Muñoz Torres M, Jodar Gimeno E, Reyes Garcia R, Martínez Diaz Guerra G, Amado JA, Gaztambide S, Quesada Gómez JM; Calcium Study Group. Muñoz Torres M, et al. J Endocrinol Invest. 2012 Dec;35(11):957-63. doi: 10.3275/8184. Epub 2011 Dec 15. J Endocrinol Invest. 2012. PMID: 22183161
Bone mineral density is decreased in hyperthyroidism.
Jódar-Gimeno E, Muñoz-Torres M, Campos-Pastor MM, Escobar-Jiménez F. Jódar-Gimeno E, et al. Clin Endocrinol (Oxf). 1994 Feb;40(2):281. doi: 10.1111/j.1365-2265.1994.tb02482.x. Clin Endocrinol (Oxf). 1994. PMID: 8137530 No abstract available.
48 results